Medicines

Use this search to find information on specific human, veterinary and herbal medicines published on the European Medicines Agency’s (EMA) website. Alternatively, you can use the site-wide search in the header above to search across all the content on the EMA website. The regulatory sections of the website contain information on medicines under evaluation, medicine shortages, medication errors, medicines for use outside the European Union (EU) and post-authorisation safety studies.

-

Table of contents

About

On 15 March 2018, the Committee for Orphan Medicinal Products (COMP) adopted a negative opinion on the orphan designation application for melatonin for the treatment of non-traumatic subarachnoid haemorrhage. A negative decision was issued by the European Commission on 16 April 2018

The sponsor applied for orphan designation on the basis of the seriousness and the rarity of the condition, as well as an assumption of potential benefit over currently available methods of treatment.

The negative opinion was based on the following reason:

  • the sponsor has not provided sufficient evidence to show that melatonin might be of significant benefit for patients with non-traumatic subarachnoid haemorrhage, compared with the authorised medicine nimodipine. The laboratory models used to assess significant benefit of the medicine did not adequately represent the condition.

Requests for designation as an orphan medicinal product are made for investigational products. Absence of orphan designation does not preclude the development of this product, including its use in clinical trials. A marketing authorisation can still be obtained if quality, safety and efficacy are demonstrated.

Key facts

Active substance
melatonin
Disease / condition
Treatment of non-traumatic subarachnoid haemorrhage
Date of decision
15/03/2018
Outcome
Negative
Orphan decision number
-

Sponsor's contact details

Therapicon Srl
Via dei Grimani 10
20144 Milan
Italy
Tel. +39 02 433 042
Fax +39 02 481 952 24
E-mail: therapic@therapicon.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating